Assignee
GENPHARM INT
US·23 granted patents·2 pending applications·37,193 citations·filing 1988–2012
Top patents by PatentIndex Score
25 records- 0199US7041871B1Transgenic non-human animals capable of producing heterologous antibodiesGENPHARM INT·Filed 2000·Granted May 9, 2006·93 cites·14 claims
- 0299US5877397ATransgenic non-human animals capable of producing heterologous antibodies of various isotypesGENPHARM INT·Filed 1994·Granted Mar 2, 1999·1.6k cites·10 claims
- 0399US5874299ATransgenic non-human animals capable of producing heterologous antibodiesGENPHARM INT·Filed 1997·Granted Feb 23, 1999·1.1k cites·7 claims
- 0499US5814318ATransgenic non-human animals for producing heterologous antibodiesGENPHARM INT·Filed 1993·Granted Sep 29, 1998·2k cites·10 claims
- 0599US5789650ATransgenic non-human animals for producing heterologous antibodiesGENPHARM INT·Filed 1992·Granted Aug 4, 1998·1.5k cites·5 claims
- 0699US5770429ATransgenic non-human animals capable of producing heterologous antibodiesGENPHARM INT·Filed 1995·Granted Jun 23, 1998·2.7k cites·16 claims
- 0799US5661016ATransgenic non-human animals capable of producing heterologous antibodies of various isotypesGENPHARM INT·Filed 1993·Granted Aug 26, 1997·4.2k cites·21 claims
- 0899US5633425ATransgenic non-human animals capable of producing heterologous antibodiesGENPHARM INT·Filed 1992·Granted May 27, 1997·4.4k cites·7 claims
- 0999US5625126ATransgenic non-human animals for producing heterologous antibodiesGENPHARM INT·Filed 1994·Granted Apr 29, 1997·4.3k cites·5 claims
- 1099US5569825ATransgenic non-human animals capable of producing heterologous antibodies of various isotypesGENPHARM INT·Filed 1991·Granted Oct 29, 1996·4.7k cites·8 claims
- 1199US5545806ARansgenic non-human animals for producing heterologous antibodiesGENPHARM INT·Filed 1992·Granted Aug 13, 1996·5.5k cites·14 claims
- 1298US5304489ADNA sequences to target proteins to the mammary gland for efficient secretionGENPHARM INT·Filed 1990·Granted Apr 19, 1994·542 cites·14 claims
- 1396US6023010ATransgenic non-human animals depleted in a mature lymphocytic cell-typeGENPHARM INT·Filed 1996·Granted Feb 8, 2000·294 cites·1 claims
- 1496US5612205AHomologous recombination in mammalian cellsGENPHARM INT·Filed 1991·Granted Mar 18, 1997·540 cites·15 claims
- 1595US7722873B2Heterologous antibodies which bind human CD4GENPHARM INT·Filed 2006·Granted May 25, 2010·36 cites·14 claims
- 1695US5789215AGene targeting in animal cells using isogenic DNA constructsGENPHARM INT·Filed 1997·Granted Aug 4, 1998·963 cites·18 claims
- 1795US5591669ATransgenic mice depleted in a mature lymphocytic cell-typeGENPHARM INT·Filed 1995·Granted Jan 7, 1997·1.5k cites·5 claims
- 1895US5434340ATransgenic mice depleted in mature T-cells and methods for making transgenic miceGENPHARM INT·Filed 1992·Granted Jul 18, 1995·134 cites·16 claims
- 1995US5175384ATransgenic mice depleted in mature t-cells and methods for making transgenic miceGENPHARM INT·Filed 1988·Granted Dec 29, 1992·351 cites·5 claims
- 2093US7084260B1High affinity human antibodies and human antibodies against human antigensGENPHARM INT·Filed 1996·Granted Aug 1, 2006·96 cites·7 claims
- 2191US5643763AMethod for making recombinant yeast artificial chromosomes by minimizing diploid doubling during matingGENPHARM INT·Filed 1994·Granted Jul 1, 1997·384 cites·22 claims
- 2282US6653113B1High efficiency gene targeting in mouse embryonic stem cellsGENPHARM INT·Filed 1999·Granted Nov 25, 2003·52 cites·23 claims
- 2375US5174986AMethod for determining oncogenic potential of a chemical compoundGENPHARM INT·Filed 1989·Granted Dec 29, 1992·51 cites·3 claims
- 2458US2004107452A1Gene targeting in animal cells using isogenic DNA constructsGENPHARM INT·Filed 2003·Application pending·0 cites
- 2557US2013039850A1Heterologous antibodies which bind human cd4GENPHARM INT·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when GENPHARM INT files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →